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was the number of oocytes retrieved per cycle. In addition, 
a cost evaluation was performed based on retrieved efficacy 
data.
Results The number of oocytes retrieved appeared to be 
higher for human menopausal gonadotropin in only 2 stud-
ies while 10 out of 13 studies showed a higher mean num-
ber of oocytes retrieved per cycle for recombinant follicle-
stimulating hormone. The results of the cost evaluation 
provided a similar cost per oocyte for both hormones.
Conclusions Recombinant follicle-stimulating hormone 
treatment resulted in a higher oocytes yield per cycle than 
human menopausal gonadotropin at similar cost per oocyte.
Keywords FSH · HMG · Human menopausal 
gonadotropin · Recombinant follicle stimulating hormone · 
Systematic review · Cost evaluation · Gonadotropins · 
Infertility · Assisted reproduction
Abstract 
Background Gonadotropins are protein hormones which 
are central to the complex endocrine system that regulates 
normal growth, sexual development, and reproductive func-
tion. There is still a lively debate on which type of gon-
adotropin medication should be used, either human meno-
pausal gonadotropin or recombinant follicle-stimulating 
hormone. The objective of the study was to perform a sys-
tematic review of the recent literature to compare recom-
binant follicle-stimulating hormone to human menopau-
sal gonadotropin with the aim to assess any differences in 
terms of efficacy and to provide a cost evaluation based on 
findings of this systematic review.
Methods The review was conducted selecting prospec-
tive, randomized, controlled trials comparing the two gon-
adotropin medications from a literature search of several 
databases. The outcome measure used to evaluate efficacy 
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Introduction
Gonadotropins are protein hormones secreted by gonado-
trope cells of the anterior pituitary of vertebrates [1], which 
are central to the complex endocrine system that regulates 
normal growth, sexual development, and reproductive func-
tion. The two key hormones, follicle-stimulating hormone 
(FSH) and luteinizing hormone (LH), act synergistically 
in reproduction, stimulating the growth and recruitment of 
immature ovarian follicles in the ovary and primary sper-
matocytes in the testis to undergo the first division of mei-
osis and to form secondary spermatocytes, in women and 
men, respectively.
Gonadotropin treatments can be used to stimulate ovu-
lation in women with low natural gonadotropin or estro-
gen levels, when clomiphene treatment has been ineffec-
tive in regulating ovulation caused by polycystic ovary 
syndrome, for developing multiple egg follicles in the 
ovaries (retrieved and used in assisted reproductive tech-
niques), in combination with intrauterine insemination 
for couples with unexplained infertility when clomiphene 
was not effective. In men, gonadotropin therapy can 
improve low sperm counts caused by low levels of natural 
gonadotropins.
For this reason, gonadotropin medications have been 
the cornerstone of infertility treatment since 1950, when 
human menopausal gonadotropin (HMG) was first intro-
duced into clinical practice [2], but clinical trials started 
only in the 1960s [3, 4] . A first alternative medication to 
HMG, which contained an equal ratio of FSH and LH, 
became available in the late 1960s; following different 
purification processes, urinary FSH (uFSH) was still urine‐
derived, but largely purified of LH [5]. The final product 
contained 150 IU of FSH and 1 IU of LH per milligram of 
protein (though not of co‐purified proteins). Further tech-
nological advances made it possible to obtain uFSH with 
even less amount of LH, and in the 1990s highly purified 
FSH (HP-FSH), which contains <0.1 IU of LH activity and 
<5 % of unidentified urinary proteins, and highly purified 
HMG (HP-HMG), with the same labeled ratio of FSH: LH 
activity of HMG, became available [6, 7].
In the late 1990’s, a different type of gonadotropin had 
been developed: using recombinant DNA technology, 
recombinant FSH (rFSH) was produced, obtaining prepara-
tions that have high purity and biological potency and are 
completely LH free [8, 9].
Following commercialization of recombinant FSH, there 
has been much controversy with regard to the type of gon-
adotropin which should be utilized. The present manuscript 
presents a systematic review of the literature comparing 
rFSH and HMG with the aim of determining differences in 
efficacy between these two compounds, as well as, a cost 
evaluation conducted from the findings of the review.
Materials and methods
The analysis in this article is based on previously con-
ducted studies, and does not involve any new studies of 
human or animal subjects performed by any of the authors.
Identification of literature
To assess the efficacy of urinary HMG and rFSH therapies, 
a literature search of the National Library of Medicine and 
the National Institutes of Health (PubMed), Medline and 
Cochrane Controlled Trials Register (i.e., CENTRAL, The 
Cochrane Library) electronic databases was performed 
using the following keywords: ‘HMG’, ‘human meno-
pausal gonadotropin’, ‘recombinant follicle stimulating 
hormone’ and ‘recombinant FSH’. Only prospective, ran-
domized, controlled trials comparing recombinant FSH 
versus HMG treatments with an adequate sample size were 
included, assuming a population of at least 15 women by 
arms to avoid potential bias due to considering small stud-
ies. No additional selection on patients characteristics, indi-
cations, treatment protocols were applied. Studies selected 
for inclusion in the review were identified by two experi-
enced health economists (C. Ripellino and A. Guasconi); 
the reference lists of review articles and included studies 
drafted by each researcher were compared in order to set 
the final eligible studies list. No attempts were made to 
contact authors for additional information.
Study selection and outcome
The outcome measure used to evaluate treatment efficacy 
was the number of oocytes retrieved per cycle.
This outcome was chosen since the number of oocytes 
retrieved is directly associated with the stimulating effect of 
gonadotropins, while other outcomes, such as live birth rate, 
depend not only on gonadotropins but also on many other 
interventions and factors (e.g., male factor, quality of lab-
oratory), making it difficult to create a direct cause–effect 
relation between ovarian stimulation and live birth rate.
Moreover, some studies investigated the association 
between egg number and live birth rate following in vitro 
fertilization treatments and suggested that the number of 
eggs is a robust surrogate parameter for clinical success 
[10, 11].
A total of 59 articles were found (Fig. 1). Subsequently, 
46 articles were excluded for the following reasons: urinary 
FSH versus recombinant FSH treatment (n = 36), duplicate 
publications (n = 2), combined analysis using two previous 
trials (n = 1), abstract availability only (n = 1), no oocytes 
outcome (n = 4), very small trial (less than 30 patients, 
n = 2). The remaining 13 studies were considered for this 
publication [12–24] (Table 1).
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Cost analysis
Cost calculations were performed using Italian treatment 
costs and findings from literature review. Starting from 
individual studies total dose (IU) and number of oocytes 
retrieved per cycle, then applying Italian gonadotropin 
prices, it was possible to obtain the cost per oocyte for each 
study.
Unit costs used were obtained from the price database 
available on the Codifa Database [25], last updated in Janu-
ary 2014, i.e. €38.58 per vial of rFSH, and €26.57 per vial 
of HMG. Only gonadotropin costs were considered, assum-
ing the cost of other resources to be identical or captured 




About half of the included studies found that rFSH was 
associated with a lower mean total dose in comparison with 
HMG (Westergaard et al. [16], Rashidi et al. [19], Andersen 
et al. [20], Hompes et al. [22], Devroey et al. [23] and Ye 
et al. [24]), while in other publications (Jansen et al. [12], 
Gordon et al. [13], NG et al. [14], Strehler et al. [15], Bal-
ash et al. [17], Kilani et al. [18] and Bosch et al. [21]) HMG 
was associated with a lower total mean dose (Table 2).
The mean total dose ranged from 1353 IU to 2624 IU 
for rFSH and from 1365 IU to 2508 IU for HMG. The 
main outcome, i.e., the number of oocytes retrieved, was 
observed to be higher for HMG in 2 studies only (Kilani 
et al. [18] and Rashidi et al. [19]); 10 out of 13 studies 
showed a higher mean number of oocytes for rFSH, while 
Westergaard et al. [16] found the same mean value for both 
rFSH and HMG. The mean number of oocytes retrieved 
ranges from 6.8 to 14.4 for rFSH and from 7.2 to 12.9 for 
HMG (Table 2).
Costs
Results of the economic evaluation are presented in 
Table 3. The ovarian stimulation with rFSH compared to 
HMG generated a cost per oocyte that varies from €65 to 
€153 for recombinant therapy and from €55 to €109 for uri-
nary therapy; thus, the difference between therapies ranges 
from −€0.1 to €77.
Fig. 1  Identification and 
selection of the studies to be 
included
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A relevant difference in the cost per oocyte between 
rFSH and HMG has been observed in Kilani et al. (€ 77) 
[18]; this cost difference is greater than the values of the 
other studies, which varied from −€0.1 to €37.
Discussion
This review evaluated efficacy in terms of number of 
oocytes retrieved per cycle and the costs, calculated 
Table 1  Characteristics of included studies
IVF in vitro fertilization, ICSI intracytoplasmic sperm injection, rFSH recombinant follicle stimulating hormone, hp-HMG highly purified 
human menopausal gonadotropin, IU international units, GnRH gonadotropin-releasing hormone, GnRH-a gonadotropin-releasing hormone ago-
nist
Population Interventions
Jansen et al. [12] 109 Women undergoing IVF rFSH vs HMG at a starting dose of 150 IU for rFSH and 
225 IU for HMG
Gordon et al. [13] 128 Women undergoing IVF rFSH vs HMG at a starting dose of 225 IU in a long luteal 
GnRHa protocol
NG et al. [14] 40 Women undergoing ICSI rFSH vs HMG at a starting dose of 300 IU for 2 days, then 
150 IU
Strehler et al. [15] 578 Women undergoing IVF or ICSI rFSH vs HMG at a starting dose from 150 to 450 IU
Westergaard et al. [16] 379 Women undergoing IVF rFSH vs HMG at a starting dose of 225 IU in a long luteal 
GnRHa protocol
Balash et al. [17] 60 Patients undergoing ICSI and having unexplained or 
male-related primary infertility
rFSH vs HMG at a starting dose of 150 IU in a long luteal 
GnRHa protocol
Kilani et al. [18] 100 Women undergoing IVF rFSH vs hp-HMG at a starting dose of 150 IU in a GnRHa 
protocol
Rashidi et al. [19] 60 Women undergoing ICSI rFSH vs HMG at a starting dose of 150 IU
Andersen et al. [20] 731 Infertile women undergoing IVF rFSH vs hp-HMG at a starting dose of 225 IU in a GnRH-
antagonist protocol
Bosch et al. [21] 280 Infertile women undergoing IVF or ICSI rFSH vs hp-HMG at a starting dose of 225 IU in a fixed 
GnRH-antagonist protocol
Hompes et al. [22] 629 Infertile women undergoing IVF rFSH vs hp-HMG at a starting dose of 150 IU in a GnRH-a 
long protocol
Devroey et al. [23] 749 Infertile patients undergoing ICSI rFSH vs hp-HMG at a starting dose of 150 IU in a GnRH-
antagonist protocol
Ye et al. [24] 127 Infertile women undergoing IVF or ICSI rFSH vs hp-HMG at a starting dose of 225 IU
Table 2  Table of outcome measures
Total dose (IU) No. of retrieved oocytes
rFSH (means ± std) HMG (means ± std) rFSH (means ± std) HMG (means ± std)
Jansen et al. [12] 1,410 ± 228 1,365 ± 228 11.2 ± 6.8 8.3 ± 6.2
Gordon et al. [13] 2,025 ± 350 1,981 ± 570 12 ± 6 10 ± 7
NG et al. [14] 1,800 ± 270 1,650 ± 270 12.6 ± 8.9 9.6 ± 8.1
Strehler et al. [15] 2,150 ± 797 1,516 ± 545 12.29 ± 7.8 9.67 ± 5.92
Westergaard et al. [16] 2,242 ± 375 2,280 ± 435 12.9 ± 6.8 12.9 ± 6.7
Balash et al. [17] 2,449 ± 885 1,922 ± 379 11.79 ± 4.55 9.1 ± 4.35
Kilani et al. [18] 2,025 ± 795 1,680 ± 530 6.8 ± 3.9 7.9 ± 4.6
Rashidi et al. [19] 2,138 ± 800 2,250 ± 800 8.7 ± 8.5 9 ± 6.2
Andersen et al. [20] 2,385 ± 622 2,508 ± 729 11.8 ± 5.7 10.0 ± 5.4
Bosch et al. [21] 2,624 ± 801 2,481 ± 994 14.4 ± 8.1 11.3 ± 6.0
Hompes et al. [22] 1,759.7 1,821.0 10.56 7.76
Devroey et al. [23] 1,353 ± 296 1,433 ± 371 10.7 ± 5.8 9.1 ± 5.2
Ye et al. [24] 2,162.7 ± 399.4 2,219 ± 502.7 10.2 ± 5.2 7.2 ± 4.2
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applying Italian treatment costs to the findings of the 
retrieved studies, of rFSH and HMG in ovarian stimulation 
protocols in infertile women. The results of this system-
atic review suggest that rFSH is likely to be more effective 
than HMG. The number of oocytes retrieved per cycle was 
higher in almost all studies considered, with a similar total 
dose used for both rFSH and HMG.
The results of the economic evaluation provided a simi-
lar cost per oocyte for rFSH and HMG (with maximum 
cost differences of €37 for Rashidi et al. [19] and €77 for 
Kilani et al. [18]).
The present study findings are in agreement with the 
results of the largest meta-analyses published to date on 
this subject [26–29].
The Cochrane review by van Wely et al. [26] comparing 
rFSH to other gonadotropins irrespective of the downregu-
lation protocol used, presented evidence of a major oocyte 
production for rFSH in comparison with HMG in most of 
the considered studies.
In the 5 trials included in the meta-analysis conducted 
by Jee et al. [27], more oocytes were retrieved in the 
rFSH group, with the exception of the trial by Kilani et al. 
[18]. In the meta-analysis by Lehert et al. [28], treatment 
with human menopausal gonadotropins resulted in fewer 
oocytes (mean difference −1.54; 95 % CI −2.53 to −0.56; 
p < 0.0001) compared to rFSH. Furthermore, a higher 
total dose of human menopausal gonadotropin was neces-
sary [mean difference 235.46 IU (95 % CI 16.62–454.30; 
p = 0.03)].
A meta-analysis conducted by Wex et al. [29] showed 
a greater number of oocytes with rFSH (mean difference 
1.96; 95 % CI 1.02–2.90). Furthermore, authors developed 
a cost-minimization model where rFSH has been found 
to be cost-saving, at 90,195 kr (€10,282 or $13,394) with 
rhFSH compared to 96,436 kr (€10,994 or $14,321) with 
HP-HMG per live-birth.
A retrospective databases chart review from 4 European 
countries investigated gonadotropins usage, oocyte and 
embryo yield, and pregnancy outcomes in IVF cycles using 
rFSH or HP-HMG have been conducted by Trew et al. 
[30]. The group demonstrated a significantly lower drug 
usage per cycle for rFSH than HP-HMG (22.6 % higher 
for HP-HMG; p < 0.01) and a significantly greater average 
oocyte yield per IVF cycle in patients treated with rFSH 
in comparison with HP-HMG (10.80 ± 6.02 for rFSH vs. 
9.77 ± 5.53 for HP-HMG; p < 0.01).
The economic evaluation presented in this study shows a 
similar cost per oocyte for rFSH and HMG, is the first costs 
analysis performed using Italian treatment costs. The minor 
cost difference found suggests that the higher unit cost of 
rFSH may be offset by a higher efficacy compared with 
HMG. Furthermore, clinicians should bear in mind that 
rFSH allows for more frozen embryo transfers than HMG, 
since it produces a greater number of oocytes; thus, it can 
be possible to reduce the number of ovarian stimulations, 
with a consequent minor overall treatment cost.
Additionally, Zhu et al. [31] found that embryo cryo-
preservation and subsequent transfer cycle under optimal 
conditions, as opposed to fresh transfer cycle, achieve 
improved synchrony between embryo and endometrial 
development, thereby enhancing the clinical outcome.
The safety and tolerability of rFSH have been exten-
sively evaluated since it became available. The most obvi-
ous clinical safety advantages arise from the high purity of 
rFSH; rFSH has been proven to have better overall tolera-
bility than any previous FSH preparation [32]. In fact, filled 
by mass manufacturing process of follitropin α eliminates 
the intrinsic variability of the rat bioassay and ensures high 
batch-to-batch and vial-to-vial consistency of rFSH con-
tent. Furthermore, analytical assessment of commercially 
available rFSH pharmaceutical products has shown that 
follitropin α filled by mass is the most consistent rFSH in 
terms of protein content [33].
In contrast, since HMG preparations are directly 
extracted from human urine, the FSH activity in the prep-
arations is highly variable between batches; the control of 
raw material of the individual contributors and the vari-
ation of purification processes are the major barriers in 
improving the quality of urinary preparations [34]. Sys-
tematic literature reviews provide an excellent method to 
address eventual deficiencies of individual trials by con-
sidering several clinical studies. However, differences 
in results among studies could exist and could depend 
on clinical trials with different design and clinical prac-
tice, rather than differences in participants and clinical 
settings.
Table 3  Table of costs
Cost per oocyte
rFSH HMG Difference in costs
Jansen et al. [12] € 64.8 € 58.3 € 6.5
Gordon et al. [13] € 86.8 € 70.2 € 16.6
NG et al. [14] € 73.5 € 60.9 € 12.6
Strehler et al. [15] € 90.0 € 55.5 € 34.4
Westergaard et al. [16] € 89.4 € 62.6 € 26.8
Balash et al. [17] € 106.9 € 74.8 € 32.0
Kilani et al. [18] € 153.2 € 75.3 € 77.8
Rashidi et al. [19] € 126.4 € 88.6 € 37.8
Andersen et al. [20] € 104.0 € 88.9 € 15.1
Bosch et al. [21] € 93.7 € 77.8 € 16.0
Hompes et al. [22] € 85.7 € 83.1 € 2.6
Devroey et al. [23] € 65.0 € 55.8 € 9.3
Ye et al. [24] € 109.1 € 109.2 −€ 0.1
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However, this review presents some limitations. Only 
peer-reviewed papers are included, hence there is the pos-
sibility of selection bias related to the publication source. 
In addition, even though the searches are done thoroughly 
through multiple major databases with cross-referencing, 
there is a possibility that some papers with pivotal findings 
for this issue have not been included in this current review. 
However, since no selection criteria on patients’ charac-
teristics, indications, or treatment protocols were applied, 
publications selected cover a wide range of interventions 
and medical settings, which are representative of the use of 
gonadotropins.
Using just the number of oocytes retrieved per cycle 
as the only outcome to evaluate the efficacy of rFSH and 
HMG could be a limitation of this analysis. Nevertheless, 
the oocytes yield per cycle could be considered a direct 
measure of gonadotropin stimulation and has been demon-
strated to be highly correlated with live birth rate [10, 11]. 
Furthermore, Stoop et al. [35] demonstrated that a higher 
number of oocytes reduces cancelation rates, reduces 
the risk for multiple pregnancies and may lead to future 
pregnancies.
Any oocyte retrieved, independently from its matura-
tion stage, was included in this analysis, due to the absence 
of information in the majority of the studies. However, 
Mehri et al. [36] showed that only mature oocytes have an 
increased fertilization rate.
The authors applied the Italian acquisition costs for HP-
HMG to all HMG medications, whether highly purified or 
not. However, only a highly purified formulation is present 
in Italy. Furthermore, the cost of production related to a 
more sophisticated process could plausibly be more expen-
sive, generating an underestimate of the costs associated 
with the HMG at a lower purification rate.
In conclusion, considering the number of oocytes 
retrieved as the best direct measure of efficient ovarian 
stimulation and considering the strong correlation between 
egg number and live birth, rFSH resulted to be more effec-
tive in comparison with HMG.
Despite a relatively high acquisition cost of rFSH, the 
use of recombinant therapy for the treatment of infertility 
in an Italian perspective generates a cost per oocyte simi-
lar to the cost associated to HMG due to higher oocytes 
yield.
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